Originally published by our sister publication Pharmacy Practice News
By Bruce Buckley
Compounding pharmacies that stepped in to fill the void caused by shortages of two brand-name semaglutide products have found themselves facing increased scrutiny from federal and state regulators as well as the brand manufacturer acting to defend its patents and trademarks.